AMPLITUDE-O (Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes), on the other hand, is a trial in which weekly subcutaneous injections of efpeglenatide (4 or 6 mg) for a median of 1.8 years led to a 27% lower risk of incident MACEs and a 32% lower risk of a composite renal outcome event than placebo among persons with T2DM and either a history of CVD or current kidney disease [39]
Platform Disclosures According to MEDVi's published materials, the platform describes itself as a patient management service
Each Part D plan determines their own formulary and the majority of the cost-sharing associated with prescriptions on their formularies
Xigduo XR is not recommended for use during pregnancy, especially during the second and third trimesters
2025 Richard Weil, M.Ed., CDE, All Rights Reserved
Coverage for virtual weight loss consultations varies by plan